Related by context. Frequent words. (Click for all words.) 66 randomized Phase III 64 placebo controlled clinical 62 CYPHER ® Stent 62 PRECiSE 62 TRITON TIMI 61 active comparator 61 prospective randomized controlled 61 multicenter clinical 61 noninferiority 61 multicenter randomized 61 TAXUS stent 60 double blinded placebo 60 label multicenter 60 RESOLUTE 60 CYPHER R Stent 60 neoadjuvant 59 TAXUS Express 59 multicenter randomized double 59 SPIRIT III 59 Phase III randomized 59 multicentre 59 placebo controlled randomized 58 prospective randomized 58 multicenter 58 label dose escalation 58 plus prednisone 58 axitinib 57 carotid artery stenting 57 multicenter study 57 nab paclitaxel 57 TAXUS 57 Phase 2a clinical 57 prospective observational 57 virologic response 57 relapsed refractory multiple myeloma 57 randomized controlled clinical 57 randomized clinical 57 SWOG 57 substudy 57 RTOG 57 Azedra 56 Phase 1b clinical 56 phase IIa 56 tanespimycin 56 carotid stenting 56 stent restenosis 56 secondary efficacy endpoints 56 Acute Myocardial Infarction 56 Phase 2b clinical 56 NSABP 56 Phase 2a trial 56 Amrubicin 56 Stent System 56 EORTC 55 blind randomized controlled 55 blind randomized placebo 55 phase IIb 55 Pivotal Trial 55 placebo controlled 55 dose escalation trial 55 Phase IIb clinical 55 Pharmacokinetic 55 composite endpoint 55 decitabine 55 Pivotal Phase III 55 imetelstat 55 TAXUS R 55 pharmacodynamics 55 prespecified 55 Phase IIa trial 55 free survival PFS 54 Myocardial Infarction 54 median PFS 54 plus gemcitabine 54 NCT# 54 Phase IIa clinical 54 randomized 54 metastatic renal cell carcinoma 54 azacitidine 54 HER2 positive metastatic breast 54 CR# vcMMAE 54 TELCYTA 54 Pivotal Phase 54 dose cohorts 54 CA4P 54 Phase 2b study 54 safety tolerability pharmacokinetics 54 Phase 1b trial 54 Coronary Stent 54 undergoing coronary artery 54 virologic 54 subgroup analyzes 54 Phase 1b 54 bosentan 53 blind randomized 53 dose regimens 53 achieved statistical significance 53 mg QD 53 XELOX 53 mg BID 53 tesmilifene